Trastuzumab deruxtecan versus treatment of physician's choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study.

Toshinari YamashitaJoo Hyuk SohnEriko TokunagaNaoki NiikuraYeon Hee ParkKeun Seok LeeYee Soo ChaeBinghe XuXiaojia WangSeock-Ah ImWei LiYen-Shen LuCecilia Orbegoso AguilarSoichiro NishijimaYuji NishiyamaMasahiro SugiharaShanu ModiJunji Tsurutani

Published in: Breast cancer (Tokyo, Japan) (2024)

ClinicalTrials.gov, NCT03734029.

Keyphrases

metastatic breast cancer
emergency department
primary care
epidermal growth factor receptor
radiation therapy
decision making
liver metastases
rectal cancer
replacement therapy
smoking cessation
open label